Abstract: A compound selected from those of formula (I): wherein: X and Y represent a group selected from hydrogen, halogen, hydroxy, alkoxy, nitro, cyano, alkyl, trihaloalkyl and NRaRb, wherein Ra and Rb are as defined in the description R1 represents hydrogen or alkyl R2 represents a group selected from hydrogen, alkyl, —OR?a, —NR?aR?b, —O-Ta-OR?a, —NR?a-Ta-NR?aR?b, —NR?a—C(O)-TaH, —O—C(O)-TaH, —O-Ta-NR?aR?b, —NR?a-Ta-OR?a, —NR?a-Ta-CO2R?a and —NR?a—C(O)-Ta-NR?aR?b, wherein R?a, R?a, R?b and Ta are as defined in the description R3 and R4 represent hydrogen or alkyl A represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH—, —C(O)—CH(R8) or —CH(R8)—C(O), wherein R5, R6, R7 and R8 are as defined in the description its isomers, N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: Compounds of formula (I): wherein: A is as defined in the description, Y represents a group selected from an oxygen atom and a methylene group, R2 represents a hydrogen atom and in that case: R3 represents a group selected from a hydrogen atom and the groups linear or branched (C1–C6)alkyl, aryl, aryl-(C1–C6)alkyl (in which the alkyl moiety is linear or branched) and SO2CF3, or R2 and R3 form a bond, R1 represents a group selected from a hydrogen atom and the groups linear or branched (C1–C6)alkyl, aryl and aryl-(C1–C6)alkyl (in which the alkyl moiety is linear or branched) or a linear or branched (C1–C6)alkylene chain, Z1 and Z2 each represent a hydrogen atom or Z1 and Z2, together with the carbon atoms carrying them, form a phenyl group. Medicaments.

Abstract: A compound selected from those of formula (I): wherein: W1 represents, together with carbon to which it is bonded, phenyl, pyridyl, Z represents a group of formula U—V as defined in the description, Q1 represents oxygen, NR2 as defined in the description, Q2 represents oxygen, NR?2 as defined in the description, X1, X2, X?1 and X?2 each represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y1, Y2, Y?1 and Y?2 each represents hydrogen, or X1 and Y1, X2 and Y2, X?1 and Y?1, X?2 and Y?2 with carbon carrying them, together form carbonyl or thiocarbonyl, R1 is as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: A compound selected from those of formula (I): wherein: X and Y represent a group selected from hydrogen, halogen, alkoxy, nitro, cyano, alkyl, alkenyl, polyhaloalkyl and —NRaRb wherein Ra and Rb are as defined in the description, Z represents oxygen or NRc wherein Rc is as defined in the description, Ar represents aryl or heteroaryl, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, alkyl, —ORa and —NRaRb wherein Ra and Rb are as defined in the description, R3 and R4 represent hydrogen or alkyl, R5 represents hydrogen, ORc, NRcRd, W1—C(W2)—U—V, W1—C(W2)—W3-T1 or Z-CO—CH?CHAr wherein Rc, Rd, W1, W2, W3, U, V, T, Z and Ar are as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: The invention relates to compounds of formula (I), wherein R1 is a group selected from hydrogen, alkyl, aryl, aryalkil, heteroaryl, heteroarylalkyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, phosphonic and Si(Ra)2Rb, Y is a group selected from HN—NH and N—R2, R3 is a hydrogen atom, an alkyl, cycloalkyl, aryl, arylalkyl group, R4 is hydrogen atom or an alkyl group, enantiomers, diastereoisomers and the salts thereof.

Abstract: A compound selected from those of formula (I): wherein: X and Y represent a group selected from hydrogen, halogen, alkoxy, nitro, cyano, alkyl, alkenyl, polyhaloalkyl and —NRaRb wherein Ra and Rb are as defined in the description, Z represents oxygen or NRc wherein Rc is as defined in the description, Ar represents aryl or heteroaryl, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, alkyl, —ORa and —NRaRb wherein Ra and Rb are as defined in the description, R3 and R4 represent hydrogen or alkyl, R5 represents hydrogen, ORc, NRcRd, W1—C(W2)—U—V, W1—C(W2)—W3-T1 or Z-CO—CH?CHAr wherein Rc, Rd, W1, W2, W3, U, V, T, Z and Ar are as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: A method for treating a living body afflicted with a cancer selected from lung and ovarian carcinoma, comprising the step of administering to the living animal body an amount of a compound selected from those of formula (I): wherein: X and Y represent group selected from hydrogen, halogen, mercapto, cyano, nitro, alkyl, trihaloalkyl, trihaloalkylcarbonylamino, —ORa, —NRaRb, —NRa—C(O)-T1, —O—C(O)-T1, —O-T2-NRaRb, —O-T2-ORa, —NRa-T2-NRaRb, —NRa-T2-ORa and —NRa-T2-CO2Ra wherein Ra, Rb, T1, T2 are as defined in the description, or X and Y together form a methylenedioxy or ethylenedioxy, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, —ORa, —NRaRb, —NRa—C(O)-T1, —O—C(O)-T1, —O-T2-NRaRb, —O-T2-ORa, —NRa-T2-NRaRb, —NRa-T2-ORa and —NRa-T2-CO2Ra wherein Ra, Rb, T1 and T2 are as defined hereinbefore, R3 and R4 represent hydrogen or alkyl, W represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH— or —C(O)—CH(R8)— wherein R5, R6, R7 and R8 are as defined in the descript

Abstract: A compound of formula (I): wherein: represents benzo or pyrido, optionally fused in the 2-3, 3-4 or 4-5 position to a phenyl, (C4-C8)cycloalkyl or heterocyclic group, which may be optionally substituted, W represents X—Y or Y—X, wherein: X represents and Y represents oxygen or N—R3, n represents zero or an integer from 1 to 6, G, R1, R2 and R3 are as defined in the description, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful for the treatment of cancerous diseases.

Abstract: Techniques for enhancing security in networking environments, whereby a cryptographic node negotiates a set of security parameters (a “security association”) with an end node, on behalf of a routing node (an “edge router”), and then securely distributes the negotiated security parameters to the edge router and/or to other edge routers in the network. The disclosed negotiation techniques allow the end node to physically move during the negotiation, yet still establish the security association, and the secure distribution enables the end node to move seamlessly through the network yet continue communicating securely. The disclosed techniques may also be used advantageously in other environments, such as clustered server environments, and allow an end node to communicate with multiple routing or server nodes for a variety of reasons (for example, during a hot-swap to a different server during fail-over or as a result of load balancing).

Abstract: Compounds of formula (I): wherein: A is as defined in the description, Y represents a group selected from an oxygen atom and a methylene group, R2 represents a hydrogen atom and in that case: R3 represents a group selected from a hydrogen atom and the groups linear or branched (C1-C6)alkyl, aryl, aryl-(C1-C6)alkyl (in which the alkyl moiety is linear or branched) and SO2CF3, or R2 and R3 form a bond, R1 represents a group selected from a hydrogen atom and the groups linear or branched (C1-C6)alkyl, aryl and aryl-(C1-C6)alkyl (in which the alkyl moiety is linear or branched) or a linear or branched (C1-C6)alkylene chain, Z1 and Z2 each represent a hydrogen atom or Z1 and Z2, together with the carbon atoms carrying them, form a phenyl group. Medicaments.

Abstract: Compounds of formula (I): wherein: W1 and W2, together with the carbon atoms to which they are bonded, represent a phenyl group or a pyridyl group, and at least one of the groups W1 or W2 represents a pyridyl group, R1 and R2 each represent a group of formula U-V as defined in the description, X and X1 each represent a hydrogen atom or a hydroxy, alkoxy, mercapto or alkylthio group, Y and Y1 each represent a hydrogen atom, or X and Y, X1 and Y1, together with the carbon atom carrying them, represent a carbonyl or thiocarbonyl group, R4 and R5 are as defined in the description, Q1, Q2 represent a hydrogen atom, or Q1 and Q2, together with the carbon atoms carrying them, form an aromatic bond. Medicaments.

Abstract: A compound selected from those of formula (I): wherein: Z represents a group of the formula U-V as defined in the description, W1 represents together with carbon to which it is bonded, phenyl, pyridyl, W2 is as defined in the description, X1, X2 each represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y1, Y2 each represents hydrogen, or X1 and Y1, X2 and Y2 with carbon carrying them, together form carbonyl or thiocarbonyl, R1 is as defined in the description, Q represents oxygen, a group NR2 as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: A compound selected from those of formula (I): wherein: W1, with the carbon atoms to which it is bonded, represents phenyl or pyridyl, Z represents a group selected from hydrogen, halogen, linear or branched (C1-C6)alkyl, aryl, aryl-(C1-C6)alkyl, aryloxy, aryl-(C1-C6)alkoxy, hydroxy and linear or branched (C1-C6)alkoxy, R1 is as defined in the description, R2 represents hydrogen or —CH2CH2O—R8, R3 and R4 each represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl, n represents an integer of from 1 to 6 inclusive, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: A compound selected from those of formula (I): wherein: B1, B2 represent carbon or nitrogen, X, Y, X1 and Y1 represent a group selected from hydrogen, halogen, hydroxy, alkoxy, nitro, cyano, trihaloalkyl and NRaRb wherein Ra and Rb are as defined in the description, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, alkyl, —OR?a, —NR?aR?b, —O-Ta-OR?a, —NR?a-Ta-NR?aR?b, NR?a—C(O)-TaH, —O—C(O)-TaH, —O-Ta-NRa?Rb?, —NR?a-Ta-OR?a, —NR?a-Ta-CO2R?a and —NR?a—C(O)-Ta-NR?aR?b wherein R?a, R?b, R?a and Ta are as defined in the description, R3, R4 represent hydrogen or alkyl, A represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH—, —C(O)—CH(R8)— or —CH(R8)—C(O)— wherein R5, R6, R7 and R8 are as defined in the description, its isomers, N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: A compound selected from these of formula (I): wherein: R1 represents hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl or phosphono, R2 represents oxygen or sulphur, R3 represents hydrogen or alkyl, cycloalkyl or arylalkyl, X represents linear or branched (C1-C6)alkylene, R4 represents a group selected from amino optionally substituted by one or two groups, —N(R3)—X1—OR5 wherein R3, X1 and R5 are as defined in the description, —N(R3)—X1—NR6R7 wherein R3, X1, R6 and R7 are as defined in the description, hydroxy, alkoxy, aryloxy, —O—X1—OR5 wherein R5 and X1 are as defined in the description, and —O—X1—NR6R7 wherein R6, R7 and X1 are as defined in the description, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base, and medical products containing the same which are useful in the treatment of cancer.

Abstract: A compound selected from those of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: A compound of formula (I): 1

Abstract: Compounds of formula (I): 1